Blomia Tropicalis (Blo t 5) IgE Test · Blood

If you live in a warm, humid climate and your asthma or stuffy nose flares without an obvious trigger, the cause may be a dust mite that standard allergy panels often overlook. Blomia tropicalis is a major mite in tropical and subtropical regions, and the protein called Blo t 5 is the single best blood marker for telling apart real Blomia allergy from cross-reactions with the more familiar Dermatophagoides mites.

This test measures Blo t 5 IgE (immunoglobulin E, the antibody class your body uses for allergic reactions) in your blood. A positive result is strongly linked to allergic asthma and rhinitis in tropical settings and can help explain symptoms that have been hard to pin down.

What This Test Actually Measures

Blo t 5 IgE is a specific allergy antibody made by your immune cells when they have learned to react to one particular protein from the Blomia tropicalis mite. It is not a hormone, enzyme, or metabolite (a small molecule your body uses or produces). It is a sign of an immune training process called sensitization, where your body has flagged this mite protein as a threat and built dedicated antibodies against it.

Blo t 5 is considered a major allergen, meaning it is one of the most frequently recognized targets in people allergic to Blomia. Across studies, between 43% and 90% of Blomia-allergic patients carry detectable IgE against Blo t 5, depending on the population. Because Blo t 5 has only limited overlap with similar proteins from the common house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae, it serves as a species-specific marker of true Blomia sensitization.

Why Knowing Your Blo t 5 Status Matters

Standard allergy testing in many places uses only Dermatophagoides extracts, the temperate-zone dust mites. If your symptoms are actually driven by Blomia, that workup can come back unremarkable while you continue to wheeze, sneeze, or wake up congested. A positive Blo t 5 IgE result identifies a specific, treatable trigger and changes what kind of allergen avoidance, medication, or immunotherapy makes sense for you.

Asthma Risk

Blo t 5 IgE is one of the most consistent markers tied to allergic asthma in tropical and subtropical populations. In asthmatic children and young adults in equatorial Africa, 43% had detectable IgE against Blo t 5, a higher rate than for several Dermatophagoides components in the same group. In Taiwanese asthmatics, 81% of those sensitized to Blomia carried Blo t 5 IgE.

The marker also tracks with how severe asthma tends to be. In a Colombian study, people sensitized to Blo t 5 alongside Ascaris had more emergency room visits for asthma. In moderate-to-severe type-2-high asthma patients, Blo t 5 and a related Blomia protein (Blo t 21) showed significantly higher IgE levels than in milder asthma, marking Blo t 5 as clinically relevant for severity in storage-mite-sensitized airways.

Allergic Rhinitis and Combined Allergic Disease

Blo t 5 sensitization is a documented risk factor for allergic rhinitis (chronic nasal allergy). In a Malaysian study of 329 allergic patients, sensitization to recombinant Blo t 5 reached 74.6% of those reactive to Blomia, and IgE to Blo t 5 carried high odds ratios for both asthma and allergic rhinitis diagnoses. Children with broad recognition across multiple Blomia components, including Blo t 5, were more likely to have the combined phenotype of asthma plus rhinitis plus atopic dermatitis.

Why a Routine Dust Mite Test Can Miss This

Many commercial Blomia skin prick test extracts contain little or no Blo t 5, which can produce a falsely reassuring negative even in someone who is genuinely Blomia-allergic. In equatorial Africa, skin testing used only Dermatophagoides extracts and missed Blo t 5 as a dominant sensitizer, identified only when blood-based molecular testing was added. If you have allergic symptoms and a Dermatophagoides-only workup looks clean, Blo t 5 IgE in blood can fill that gap.

Tracking Your Trend

A single Blo t 5 IgE reading tells you whether sensitization is present today. Tracking the marker over time is more useful for two reasons. First, it lets you see whether your immune response to this mite is intensifying, stable, or fading, which can shift as your environment, climate exposure, and treatments change. Second, if you start allergen immunotherapy aimed at house dust mites, repeated testing can help document how your antibody profile is shifting alongside symptom changes.

A reasonable cadence is a baseline test, a follow-up at 6 to 12 months if your symptoms or environment change, and at least annual checks if you are on immunotherapy or actively managing tropical-region mite exposure.

When Results Can Be Misleading

• Test-method disagreement: skin prick tests and blood IgE for Blomia agree only about two-thirds of the time. In one cohort, 32.5% of patients had discordant skin and blood results for Blomia, with only fair statistical agreement between methods.
• Older age: skin test wheal sizes shrink with age, which can produce a negative skin test in someone who still has clearly positive blood Blo t 5 IgE.
• Cross-reactivity caveats: Blo t 5 has limited but real cross-reactivity with Der p 5 and Der p 21 from Dermatophagoides mites. If you are heavily sensitized to common house dust mites, a small portion of your Blo t 5 signal may reflect cross-recognition rather than direct Blomia exposure.
• Local versus systemic IgE: some people with strong nasal mite allergy produce IgE mainly in the nasal lining rather than the bloodstream. A negative blood Blo t 5 IgE does not fully rule out mite-driven nasal allergy if symptoms are clearly suggestive.

What to Do With an Out-of-Pattern Result

A positive Blo t 5 IgE alongside compatible symptoms (chronic congestion, recurrent wheezing, nighttime cough, eye itch in tropical or subtropical climates) is a strong signal to pursue mite-focused allergy care. Useful next steps include broadening the workup with whole-extract IgE to Blomia, Der p, and Der f to see the full mite picture, adding other Blomia components such as Blo t 2, Blo t 7, and Blo t 21 to map the breadth of sensitization, and considering Der p 2 to clarify how much of your disease is Dermatophagoides-driven versus Blomia-driven.

If your symptoms are significant, an allergist or immunologist can use the Blo t 5 result to decide whether allergen immunotherapy with extracts that actually contain Blomia tropicalis is appropriate, since standard house dust mite immunotherapy may not adequately cover this species. A positive Blo t 5 result in someone with no symptoms is not, on its own, a reason to start treatment; it is information to monitor.